https://pubmed.ncbi.nlm.nih.gov/31992506-molecular-profiling-of-gynecologic-cancers-for-treatment-and-management-of-disease-demonstrating-clinical-significance-using-the-ampascocap-guidelines-for-interpretation-and-reporting-of-somatic-variants/?dopt=Abstract

Molecular Profiling of Gynecologic Cancers for Treatment and Management of Disease - Demonstrating Clinical Significance Using the AMP/ASCO/CAP Guidelines for Interpretation and Reporting of Somatic Variants

Qian Nie 1, Gregory Omerza 1, Harshpreet Chandok 1, Matthew Prego 1, Meng-Chang Hsiao 1, Bridgette Meyers 1, Andrew Hesse 1, Jasmina Uvalic 1, Melissa Soucy 1, Daniel Bergeron 1, Michael Peracchio 1, Shelbi Burns 1, Kevin Kelly 1, Shannon Rowe 1, Jens Rueter 2, Honey V Reddi 3

Affiliations 

• PMID: 31992506
 
• DOI: 10.1016/j.cancergen.2019.11.008

Abstract

Molecular features of gynecologic cancers have been investigated in comprehensive studies, but correlation of these molecular signatures with clinical significance for precision medicine is yet to be established. Towards this end, we evaluated 95 gynecologic cancer cases submitted for testing using The JAX ActionSeq™ NGS panel. Molecular profiles were studied and compared to TCGA datasets to identify similarities and distinguishing features among subtypes. We identified 146 unique clinically significant variants (Tier I and II) across 45 of the 212 genes (21%), in 87% (83/95) of cases. TP53, PTEN, ARID1A, PIK3CA and ATM were the most commonly mutated genes; CCNE1 and ERBB2 amplifications were the most frequently detected copy-number alterations. PARP inhibitors were among the most commonly reported drug class with clinical trials, consistent with the frequency of DNA damage-response pathway mutations in our cohort. Overall, our study provides additional insight into the molecular profiles of gynecologic cancers, highlighting regulatory pathways involved, raising the potential implications for targeted therapeutic options currently available.

Keywords: Gynecological cancers; Molecular profiling; Next-generation sequencing.

Copyright © 2020. Published by Elsevier Inc.

Conflict of interest statement

Declaration of Competing Interest The authors declare no relevant conflict of interest.

Similar articles

• Molecular Profiling of CNS Tumors for the Treatment and Management of Disease

  Q Nie et al. J Clin Neurosci 71, 311-315. Jan 2020. PMID 31859178.

  The World Health Organization (WHO) has defined more than 130 distinct central nervous system (CNS) tumor entities, of which glioblastoma is the most fatal primary brain …
• Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay

  P Selvam et al. Mol Diagn Ther. 2019. PMID 31754995.

  This study demonstrates that of the genes with documented involvement in cancer, only a limited number are currently clinically significant from a therapeutic, diagnostic …
• Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers

  WL Shaib et al. Oncologist. 2019. PMID 31784493.

  Evaluation of ctDNA is feasible among patients with AC. The frequency of genomic alterations is similar to that previously reported in tissue NGS. Liquid biopsies are not …
• Genomic Profiling of Gynecologic Cancers and Implications for Clinical Practice

  EN Prendergast et al. Curr Opin Obstet Gynecol 29 (1), 18-25. Feb 2017. PMID 27984344. - Review

  Identification of molecular subsets with distinct clinical attributes, prognostic significance, and targeted therapy directed options is now feasible in clinical gynecolo …
• Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer

  L Santarpia et al. Oncologist 21 (9), 1063-78. Sep 2016. PMID 27384237. - Review

  Next-generation sequencing is now widely available in the clinic, but interpretation of the results is challenging, and its impact on treatment selection is often limited …